{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T02:54:00Z","timestamp":1782528840543,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1136\/ijgc-2024-005363","type":"journal-article","created":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T21:40:17Z","timestamp":1718055617000},"page":"1588-1595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients"],"prefix":"10.1016","volume":"34","author":[{"given":"Matteo","family":"Bruno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4614-9261","authenticated-orcid":false,"given":"Adriana Ionelia","family":"Apostol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5434-1263","authenticated-orcid":false,"given":"Serena Maria","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Maria","family":"Sassu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Culcasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0981-0598","authenticated-orcid":false,"given":"Domenica","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2758-1063","authenticated-orcid":false,"given":"Giovanni","family":"Scambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-335X","authenticated-orcid":false,"given":"Anna","family":"Fagotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7098-8956","authenticated-orcid":false,"given":"Claudia","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2024-005363_bb0010","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/jnci\/95.2.113","article-title":"Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer\u2013Adjuvant ChemoTherapy in Ovarian Neoplasm Trial","volume":"95","author":"Trimbos","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2024-005363_bb0015","unstructured":"Cancer Stat Facts: Ovarian Cancer . National Cancer Institute: Surveillance, Epidemiology, and End Results Program, Available: https:\/\/seer.cancer.gov\/statfacts\/html\/ovary.html"},{"key":"10.1136\/ijgc-2024-005363_bb0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ygyno.2007.08.075","volume":"108","author":"Alberts","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005363_bb0025","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ygyno.2020.09.006","article-title":"Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo results from the phase III ENGOT-OV16\/NOVA trial","volume":"159","author":"Mirza","year":"2020","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005363_bb0030","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","article-title":"Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind,placebo-controlled phase III trial","volume":"32","author":"Wu","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005363_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ygyno.2019.04.017","article-title":"Baseline platelet count and body weight as predictors of early dose modification in the QUADRA trial of niraparib monotherapy for the treatment of heavily pretreated (\u22654th line), advanced, recurrent high-grade serous ovarian cancer","volume":"154","author":"Matulonis","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2024-005363_bb0040","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2024-005363_bb0045","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer: a phase 3 randomized clinical trial","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2024-005363_bb0050","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"10.1136\/ijgc-2024-005363_bb0055","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/emboj.2009.206","article-title":"PARP is activated at stalled forks to mediate Mre11- dependent replication restart and recombination","volume":"28","author":"Bryant","year":"2009","journal-title":"EMBO J"},{"key":"10.1136\/ijgc-2024-005363_bb0060","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1038\/sj.onc.1207491","article-title":"Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but Com- promises the reactivation of stalled replication forks","volume":"23","author":"Yang","year":"2004","journal-title":"Oncogene"},{"key":"10.1136\/ijgc-2024-005363_bb0065","author":"GlaxoSmithKline","year":"2020","journal-title":"ZEJULA (Niraparib): US prescribing information"},{"key":"10.1136\/ijgc-2024-005363_bb0070","author":"GlaxoSmithKline","year":"2020","journal-title":"ZEJULA (Niraparib): summary of product characteristics"},{"key":"10.1136\/ijgc-2024-005363_bb0075","author":"GSK","year":"2022","journal-title":"GSK provides an update on Zejula (niraparib) US prescribing information"},{"key":"10.1136\/ijgc-2024-005363_bb0080","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdy181","article-title":"Safety and dose modification for patients receiving niraparib","volume":"29","author":"Berek","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005363_bb0085","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.annonc.2022.11.007","article-title":"Vp7-2022: an ad-hoc interim overall survival results of niraparib with individualized starting dose as maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer (NORA): a double-blind, randomized, placebo-controlled, phase III trial","volume":"34","author":"Mirza","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005363_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.658","article-title":"530P PRIMA\/ENGOT-OV26\/GOG-3012 study: updated long-term PFS and safety","volume":"33","author":"Gonzalez Martin","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005363_bb0095","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/cncr.34706","article-title":"Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"129","author":"Mirza","year":"2023","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2024-005363_bb0100","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","article-title":"Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial","volume":"20","author":"Moore","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2024-005363_bb0105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2024-005363_bb0110","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1136\/ijgc-2022-004079","article-title":"Safety and management of niraparib monotherapy in ovarian cancer clinical trials","volume":"33","author":"Monk","year":"2023","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2024-005363_bb0115","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s11523-016-0435-8","article-title":"An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor olaparib","volume":"11","author":"Mateo","year":"2016","journal-title":"Target Oncol"},{"key":"10.1136\/ijgc-2024-005363_bb0120","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.annonc.2022.02.222","article-title":"The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2\/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer","volume":"33","author":"Francis","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2024-005363_bb0125","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.2217\/fon-2019-0471","article-title":"Real-world adverse events with niraparib 200 mg\/day maintenance therapy in ovarian cancer: a retrospective study","volume":"15","author":"Gallagher","year":"2019","journal-title":"Future Oncol"},{"key":"10.1136\/ijgc-2024-005363_bb0130","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/curroncol29010029","article-title":"Safety profile of niraparib as maintenance therapy for ovarian cancer: a systematic review and meta-analysis","volume":"29","author":"Pagkali","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1136\/ijgc-2024-005363_bb0135","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s11523-023-00999-x","article-title":"Efficacy and safety of niraparib as first-line maintenance treatment for patients with advanced ovarian cancer: real-world data from a multicenter study in China","volume":"18","author":"Zhao","year":"2023","journal-title":"Target Oncol"},{"key":"10.1136\/ijgc-2024-005363_bb0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00280-017-3455-x","article-title":"Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients","volume":"81","author":"van Andel","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1136\/ijgc-2024-005363_bb0145","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s10147-022-02163-3","article-title":"Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs","volume":"27","author":"Nakai","year":"2022","journal-title":"Int J Clin Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24035734?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24035734?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2024-005363","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T20:30:59Z","timestamp":1759350659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24035734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1048891X24035734"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2024-005363","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2024-005363","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2024. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}